356 related articles for article (PubMed ID: 32696396)
1. A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
Hu K; Wang M; Zhao Y; Zhang Y; Wang T; Zheng Z; Li X; Zeng S; Zhao D; Li H; Xu K; Lan K
Virol Sin; 2020 Dec; 35(6):725-733. PubMed ID: 32696396
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Kaur H; Sarma P; Bhattacharyya A; Sharma S; Chhimpa N; Prajapat M; Prakash A; Kumar S; Singh A; Singh R; Avti P; Thota P; Medhi B
Eur J Pharmacol; 2021 Sep; 906():174233. PubMed ID: 34111397
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial.
Wang M; Zhao Y; Hu W; Zhao D; Zhang Y; Wang T; Zheng Z; Li X; Zeng S; Liu Z; Lu L; Wan Z; Hu K
Clin Infect Dis; 2021 Dec; 73(11):e4012-e4019. PubMed ID: 32955081
[TBL] [Abstract][Full Text] [Related]
4. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment and Consulting Doctor Later: A Retrospective Cohort Study.
He XL; Zhou YY; Fu W; Xue YE; Liang MY; Yang BH; Ma WL; Zhou Q; Chen L; Zhang JC; Wang XR
Curr Med Sci; 2021 Dec; 41(6):1096-1104. PubMed ID: 34515914
[TBL] [Abstract][Full Text] [Related]
5. IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Hahn F; Wangen C; Häge S; Peter AS; Dobler G; Hurst B; Julander J; Fuchs J; Ruzsics Z; Überla K; Jäck HM; Ptak R; Muehler A; Gröppel M; Vitt D; Peelen E; Kohlhof H; Marschall M
Viruses; 2020 Dec; 12(12):. PubMed ID: 33291455
[TBL] [Abstract][Full Text] [Related]
6. Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Xiong R; Zhang L; Li S; Sun Y; Ding M; Wang Y; Zhao Y; Wu Y; Shang W; Jiang X; Shan J; Shen Z; Tong Y; Xu L; Chen Y; Liu Y; Zou G; Lavillete D; Zhao Z; Wang R; Zhu L; Xiao G; Lan K; Li H; Xu K
Protein Cell; 2020 Oct; 11(10):723-739. PubMed ID: 32754890
[TBL] [Abstract][Full Text] [Related]
7. Interferon-α2b spray inhalation did not shorten virus shedding time of SARS-CoV-2 in hospitalized patients: a preliminary matched case-control study.
Hao SR; Yan R; Zhang SY; Lian JS; Cai H; Zhang XL; Zheng L; Jia HY; Hu JH; Yu GD; Gu JQ; Ye CY; Jin CL; Lu YF; Xin JJ; Sheng JF; Yang YD
J Zhejiang Univ Sci B; 2020 Aug.; 21(8):628-636. PubMed ID: 32748578
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Niclosamide vs Placebo in SARS-CoV-2 Respiratory Viral Clearance, Viral Shedding, and Duration of Symptoms Among Patients With Mild to Moderate COVID-19: A Phase 2 Randomized Clinical Trial.
Cairns DM; Dulko D; Griffiths JK; Golan Y; Cohen T; Trinquart L; Price LL; Beaulac KR; Selker HP
JAMA Netw Open; 2022 Feb; 5(2):e2144942. PubMed ID: 35138402
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial.
Feld JJ; Kandel C; Biondi MJ; Kozak RA; Zahoor MA; Lemieux C; Borgia SM; Boggild AK; Powis J; McCready J; Tan DHS; Chan T; Coburn B; Kumar D; Humar A; Chan A; O'Neil B; Noureldin S; Booth J; Hong R; Smookler D; Aleyadeh W; Patel A; Barber B; Casey J; Hiebert R; Mistry H; Choong I; Hislop C; Santer DM; Lorne Tyrrell D; Glenn JS; Gehring AJ; Janssen HLA; Hansen BE
Lancet Respir Med; 2021 May; 9(5):498-510. PubMed ID: 33556319
[TBL] [Abstract][Full Text] [Related]
10. Ivermectin for preventing and treating COVID-19.
Popp M; Stegemann M; Metzendorf MI; Gould S; Kranke P; Meybohm P; Skoetz N; Weibel S
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD015017. PubMed ID: 34318930
[TBL] [Abstract][Full Text] [Related]
11. Leflunomide an immunomodulator with antineoplastic and antiviral potentials but drug-induced liver injury: A comprehensive review.
Alamri RD; Elmeligy MA; Albalawi GA; Alquayr SM; Alsubhi SS; El-Ghaiesh SH
Int Immunopharmacol; 2021 Apr; 93():107398. PubMed ID: 33571819
[TBL] [Abstract][Full Text] [Related]
12. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
13. A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses.
Zheng Y; Li S; Song K; Ye J; Li W; Zhong Y; Feng Z; Liang S; Cai Z; Xu K
Viruses; 2022 Apr; 14(5):. PubMed ID: 35632670
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
[TBL] [Abstract][Full Text] [Related]
15. Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial.
Jagannathan P; Andrews JR; Bonilla H; Hedlin H; Jacobson KB; Balasubramanian V; Purington N; Kamble S; de Vries CR; Quintero O; Feng K; Ley C; Winslow D; Newberry J; Edwards K; Hislop C; Choong I; Maldonado Y; Glenn J; Bhatt A; Blish C; Wang T; Khosla C; Pinsky BA; Desai M; Parsonnet J; Singh U
Nat Commun; 2021 Mar; 12(1):1967. PubMed ID: 33785743
[TBL] [Abstract][Full Text] [Related]
16. Clinical course and treatment efficacy of COVID-19 near Hubei Province, China: A multicentre, retrospective study.
Zeng QL; Li GM; Ji F; Ma SH; Zhang GF; Xu JH; Lin WB; Xu GH; Zhang GQ; Li GT; Cui GL; Liu N; Zeng FJ; Ai ZG; Xu GF; Liu N; Liang J; Zhang MM; Li C; Zhang ZH; Wang ZS; Li Z; Yu ZJ
Transbound Emerg Dis; 2020 Nov; 67(6):2971-2982. PubMed ID: 32531138
[TBL] [Abstract][Full Text] [Related]
17. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
[TBL] [Abstract][Full Text] [Related]
18. Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
Coelho AR; Oliveira PJ
Eur J Clin Invest; 2020 Oct; 50(10):e13366. PubMed ID: 32735689
[No Abstract] [Full Text] [Related]
19. Inhibitors of endosomal acidification suppress SARS-CoV-2 replication and relieve viral pneumonia in hACE2 transgenic mice.
Shang C; Zhuang X; Zhang H; Li Y; Zhu Y; Lu J; Ge C; Cong J; Li T; Tian M; Jin N; Li X
Virol J; 2021 Feb; 18(1):46. PubMed ID: 33639976
[TBL] [Abstract][Full Text] [Related]
20. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
